Market closed
Phio Pharmaceuticals Corp./$PHIO
Phio Pharmaceuticals shares are trading higher after a safety committee approved advancing their skin cancer drug to the next dose level in a phase I study.
7 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Ticker
$PHIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
5
Website
PHIO Metrics
BasicAdvanced
$11M
-
-$9.08
1.08
-
Price and volume
Market cap
$11M
Beta
1.08
52-week high
$2.73
52-week low
$0.97
Average daily volume
5.5M
Financial strength
Current ratio
5.651
Quick ratio
5.302
Management effectiveness
Return on assets (TTM)
-61.14%
Return on equity (TTM)
-114.83%
Valuation
Price to book
0.81
Price to tangible book (TTM)
0.81
Price to free cash flow (TTM)
-0.244
Growth
Earnings per share change (TTM)
-80.58%
3-year earnings per share growth (CAGR)
-56.70%
PHIO News
AllArticlesVideos
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
Newsfile Corp·7 days ago
Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894
Newsfile Corp·2 weeks ago
Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update
Newsfile Corp·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Phio Pharmaceuticals Corp. stock?
Phio Pharmaceuticals Corp. (PHIO) has a market cap of $11M as of April 16, 2025.
What is the P/E ratio for Phio Pharmaceuticals Corp. stock?
The price to earnings (P/E) ratio for Phio Pharmaceuticals Corp. (PHIO) stock is 0 as of April 16, 2025.
Does Phio Pharmaceuticals Corp. stock pay dividends?
No, Phio Pharmaceuticals Corp. (PHIO) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Phio Pharmaceuticals Corp. dividend payment date?
Phio Pharmaceuticals Corp. (PHIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Phio Pharmaceuticals Corp.?
Phio Pharmaceuticals Corp. (PHIO) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.